nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ESR1—breast cancer	0.122	0.42	CbGaD
Naloxone—ESR1—Toremifene—breast cancer	0.0635	0.14	CbGbCtD
Naloxone—ESR1—Fluoxymesterone—breast cancer	0.0635	0.14	CbGbCtD
Naloxone—CYP3A4—breast cancer	0.0622	0.214	CbGaD
Naloxone—ESR1—Fulvestrant—breast cancer	0.059	0.13	CbGbCtD
Naloxone—ALB—breast cancer	0.0543	0.187	CbGaD
Naloxone—ABCB1—breast cancer	0.0518	0.178	CbGaD
Naloxone—ESR1—Raloxifene—breast cancer	0.0351	0.0775	CbGbCtD
Naloxone—SLCO1A2—Chlorambucil—breast cancer	0.0334	0.0736	CbGbCtD
Naloxone—ESR1—Tamoxifen—breast cancer	0.0232	0.0512	CbGbCtD
Naloxone—CYP2C8—Lapatinib—breast cancer	0.0117	0.0259	CbGbCtD
Naloxone—ABCB1—Toremifene—breast cancer	0.0109	0.024	CbGbCtD
Naloxone—CYP3A4—Exemestane—breast cancer	0.0094	0.0208	CbGbCtD
Naloxone—CYP2C8—Raloxifene—breast cancer	0.00888	0.0196	CbGbCtD
Naloxone—CYP3A4—Letrozole—breast cancer	0.00799	0.0177	CbGbCtD
Naloxone—ABCB1—Lapatinib—breast cancer	0.00793	0.0175	CbGbCtD
Naloxone—CYP3A4—Anastrozole—breast cancer	0.00713	0.0157	CbGbCtD
Naloxone—CYP3A4—Toremifene—breast cancer	0.00652	0.0144	CbGbCtD
Naloxone—CYP3A4—Fulvestrant—breast cancer	0.00606	0.0134	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—breast cancer	0.00597	0.0132	CbGbCtD
Naloxone—CYP2C8—Tamoxifen—breast cancer	0.00587	0.013	CbGbCtD
Naloxone—ALB—Irinotecan—breast cancer	0.00583	0.0129	CbGbCtD
Naloxone—ALB—Fluorouracil—breast cancer	0.0056	0.0124	CbGbCtD
Naloxone—CYP3A4—Thiotepa—breast cancer	0.0054	0.0119	CbGbCtD
Naloxone—CYP3A4—Ixabepilone—breast cancer	0.00494	0.0109	CbGbCtD
Naloxone—CYP3A4—Lapatinib—breast cancer	0.00475	0.0105	CbGbCtD
Naloxone—CYP2C8—Paclitaxel—breast cancer	0.00457	0.0101	CbGbCtD
Naloxone—ABCB1—Vinorelbine—breast cancer	0.0044	0.00972	CbGbCtD
Naloxone—CYP2C8—Fluorouracil—breast cancer	0.00433	0.00955	CbGbCtD
Naloxone—ABCB1—Tamoxifen—breast cancer	0.00397	0.00877	CbGbCtD
Naloxone—ABCB1—Mitoxantrone—breast cancer	0.00388	0.00856	CbGbCtD
Naloxone—CYP3A4—Raloxifene—breast cancer	0.0036	0.00795	CbGbCtD
Naloxone—ABCB1—Gemcitabine—breast cancer	0.00342	0.00756	CbGbCtD
Naloxone—ABCB1—Paclitaxel—breast cancer	0.00309	0.00683	CbGbCtD
Naloxone—ALB—Methotrexate—breast cancer	0.00309	0.00681	CbGbCtD
Naloxone—ABCB1—Irinotecan—breast cancer	0.00305	0.00674	CbGbCtD
Naloxone—ABCB1—Vinblastine—breast cancer	0.00271	0.00599	CbGbCtD
Naloxone—CYP3A4—Vinorelbine—breast cancer	0.00264	0.00582	CbGbCtD
Naloxone—CYP3A4—Tamoxifen—breast cancer	0.00238	0.00526	CbGbCtD
Naloxone—CYP3A4—Mitoxantrone—breast cancer	0.00232	0.00513	CbGbCtD
Naloxone—ABCB1—Docetaxel—breast cancer	0.00224	0.00494	CbGbCtD
Naloxone—TLR4—endometrium—breast cancer	0.0022	0.0638	CbGeAlD
Naloxone—TLR4—adipose tissue—breast cancer	0.00198	0.0575	CbGeAlD
Naloxone—CREB1—mammary gland—breast cancer	0.00194	0.0562	CbGeAlD
Naloxone—CYP3A4—Paclitaxel—breast cancer	0.00185	0.00409	CbGbCtD
Naloxone—CYP3A4—Irinotecan—breast cancer	0.00183	0.00404	CbGbCtD
Naloxone—TLR4—adrenal gland—breast cancer	0.00178	0.0516	CbGeAlD
Naloxone—TLR4—bone marrow—breast cancer	0.00172	0.0499	CbGeAlD
Naloxone—ABCB1—Doxorubicin—breast cancer	0.00167	0.00368	CbGbCtD
Naloxone—TLR4—female gonad—breast cancer	0.00166	0.0481	CbGeAlD
Naloxone—CYP3A4—Vinblastine—breast cancer	0.00163	0.00359	CbGbCtD
Naloxone—ABCB1—Methotrexate—breast cancer	0.00161	0.00356	CbGbCtD
Naloxone—CYP3A4—Docetaxel—breast cancer	0.00134	0.00296	CbGbCtD
Naloxone—CREB1—embryo—breast cancer	0.00132	0.0384	CbGeAlD
Naloxone—CREB1—epithelium—breast cancer	0.00108	0.0313	CbGeAlD
Naloxone—TLR4—lymph node—breast cancer	0.00107	0.0309	CbGeAlD
Naloxone—CREB1—skin of body—breast cancer	0.00103	0.0298	CbGeAlD
Naloxone—CYP3A4—Doxorubicin—breast cancer	0.000999	0.0022	CbGbCtD
Naloxone—CREB1—endometrium—breast cancer	0.000968	0.0281	CbGeAlD
Naloxone—ALB—mammary gland—breast cancer	0.000894	0.0259	CbGeAlD
Naloxone—CREB1—uterus—breast cancer	0.000892	0.0259	CbGeAlD
Naloxone—CREB1—pituitary gland—breast cancer	0.000876	0.0254	CbGeAlD
Naloxone—CREB1—adipose tissue—breast cancer	0.000872	0.0253	CbGeAlD
Naloxone—CREB1—female reproductive system—breast cancer	0.000802	0.0233	CbGeAlD
Naloxone—CREB1—adrenal gland—breast cancer	0.000783	0.0227	CbGeAlD
Naloxone—ESR1—mammary gland—breast cancer	0.000763	0.0221	CbGeAlD
Naloxone—CREB1—bone marrow—breast cancer	0.000757	0.022	CbGeAlD
Naloxone—CREB1—female gonad—breast cancer	0.00073	0.0212	CbGeAlD
Naloxone—CREB1—endocrine gland—breast cancer	0.000679	0.0197	CbGeAlD
Naloxone—CYP2C8—mammary gland—breast cancer	0.000629	0.0182	CbGeAlD
Naloxone—OPRK1—female reproductive system—breast cancer	0.000608	0.0176	CbGeAlD
Naloxone—ESR1—embryo—breast cancer	0.000521	0.0151	CbGeAlD
Naloxone—CREB1—lymph node—breast cancer	0.000469	0.0136	CbGeAlD
Naloxone—ESR1—epithelium—breast cancer	0.000425	0.0123	CbGeAlD
Naloxone—ESR1—endometrium—breast cancer	0.000381	0.0111	CbGeAlD
Naloxone—OPRM1—endocrine gland—breast cancer	0.000366	0.0106	CbGeAlD
Naloxone—ALB—adrenal gland—breast cancer	0.000361	0.0105	CbGeAlD
Naloxone—ESR1—uterus—breast cancer	0.000351	0.0102	CbGeAlD
Naloxone—ESR1—pituitary gland—breast cancer	0.000345	0.01	CbGeAlD
Naloxone—ESR1—adipose tissue—breast cancer	0.000343	0.00996	CbGeAlD
Naloxone—ESR1—female reproductive system—breast cancer	0.000316	0.00916	CbGeAlD
Naloxone—SLCO1A2—endocrine gland—breast cancer	0.000315	0.00914	CbGeAlD
Naloxone—CYP2C8—endometrium—breast cancer	0.000314	0.00911	CbGeAlD
Naloxone—ESR1—adrenal gland—breast cancer	0.000308	0.00894	CbGeAlD
Naloxone—ESR1—female gonad—breast cancer	0.000287	0.00833	CbGeAlD
Naloxone—CYP2C8—pituitary gland—breast cancer	0.000284	0.00824	CbGeAlD
Naloxone—ESR1—endocrine gland—breast cancer	0.000267	0.00775	CbGeAlD
Naloxone—CYP2C8—female reproductive system—breast cancer	0.00026	0.00754	CbGeAlD
Naloxone—CYP2C8—endocrine gland—breast cancer	0.00022	0.00638	CbGeAlD
Naloxone—ALB—lymph node—breast cancer	0.000216	0.00628	CbGeAlD
Naloxone—ABCB1—embryo—breast cancer	0.000206	0.00597	CbGeAlD
Naloxone—Methylnaltrexone—CYP2D6—breast cancer	0.000198	0.0947	CrCbGaD
Naloxone—Buprenorphine—ABCG2—breast cancer	0.000186	0.089	CrCbGaD
Naloxone—ESR1—lymph node—breast cancer	0.000185	0.00536	CbGeAlD
Naloxone—CYP3A4—female reproductive system—breast cancer	0.000176	0.00511	CbGeAlD
Naloxone—ABCB1—epithelium—breast cancer	0.000168	0.00487	CbGeAlD
Naloxone—Hydromorphone—PTGS1—breast cancer	0.000157	0.0751	CrCbGaD
Naloxone—ABCB1—endometrium—breast cancer	0.000151	0.00437	CbGeAlD
Naloxone—CYP3A4—endocrine gland—breast cancer	0.000149	0.00432	CbGeAlD
Naloxone—Oxymorphone—CYP2D6—breast cancer	0.000148	0.0706	CrCbGaD
Naloxone—ABCB1—uterus—breast cancer	0.000139	0.00402	CbGeAlD
Naloxone—ABCB1—pituitary gland—breast cancer	0.000136	0.00395	CbGeAlD
Naloxone—ABCB1—adipose tissue—breast cancer	0.000136	0.00394	CbGeAlD
Naloxone—Hydrocodone—CYP2D6—breast cancer	0.000129	0.0617	CrCbGaD
Naloxone—Oxymorphone—CYP3A4—breast cancer	0.000127	0.0606	CrCbGaD
Naloxone—ABCB1—female reproductive system—breast cancer	0.000125	0.00362	CbGeAlD
Naloxone—ABCB1—adrenal gland—breast cancer	0.000122	0.00353	CbGeAlD
Naloxone—Oxycodone—CYP2D6—breast cancer	0.000118	0.0563	CrCbGaD
Naloxone—ABCB1—bone marrow—breast cancer	0.000118	0.00341	CbGeAlD
Naloxone—ABCB1—female gonad—breast cancer	0.000113	0.00329	CbGeAlD
Naloxone—Hydrocodone—CYP3A4—breast cancer	0.000111	0.0529	CrCbGaD
Naloxone—Buprenorphine—CYP2D6—breast cancer	0.000109	0.0519	CrCbGaD
Naloxone—Paraesthesia—Vinorelbine—breast cancer	0.000108	0.00116	CcSEcCtD
Naloxone—Hydromorphone—CYP2D6—breast cancer	0.000107	0.0511	CrCbGaD
Naloxone—Dyspnoea—Vinorelbine—breast cancer	0.000107	0.00115	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—breast cancer	0.000106	0.00114	CcSEcCtD
Naloxone—Abdominal pain—Goserelin—breast cancer	0.000106	0.00114	CcSEcCtD
Naloxone—Body temperature increased—Goserelin—breast cancer	0.000106	0.00114	CcSEcCtD
Naloxone—Naltrexone—ABCB1—breast cancer	0.000106	0.0504	CrCbGaD
Naloxone—ABCB1—endocrine gland—breast cancer	0.000106	0.00306	CbGeAlD
Naloxone—Cardiac disorder—Paclitaxel—breast cancer	0.000105	0.00113	CcSEcCtD
Naloxone—Flushing—Paclitaxel—breast cancer	0.000105	0.00113	CcSEcCtD
Naloxone—Convulsion—Mitoxantrone—breast cancer	0.000105	0.00113	CcSEcCtD
Naloxone—Hypertension—Irinotecan—breast cancer	0.000105	0.00112	CcSEcCtD
Naloxone—Hypertension—Mitoxantrone—breast cancer	0.000105	0.00112	CcSEcCtD
Naloxone—Asthenia—Vinblastine—breast cancer	0.000104	0.00111	CcSEcCtD
Naloxone—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000103	0.00111	CcSEcCtD
Naloxone—Depression—Capecitabine—breast cancer	0.000103	0.00111	CcSEcCtD
Naloxone—Angiopathy—Paclitaxel—breast cancer	0.000103	0.00111	CcSEcCtD
Naloxone—Paraesthesia—Thiotepa—breast cancer	0.000103	0.0011	CcSEcCtD
Naloxone—Pain—Vinorelbine—breast cancer	0.000103	0.0011	CcSEcCtD
Naloxone—Mediastinal disorder—Paclitaxel—breast cancer	0.000102	0.0011	CcSEcCtD
Naloxone—Hypertension—Gemcitabine—breast cancer	0.000102	0.0011	CcSEcCtD
Naloxone—Chills—Paclitaxel—breast cancer	0.000102	0.00109	CcSEcCtD
Naloxone—Oxycodone—CYP3A4—breast cancer	0.000101	0.0483	CrCbGaD
Naloxone—Asthenia—Tamoxifen—breast cancer	0.000101	0.00108	CcSEcCtD
Naloxone—Convulsion—Fluorouracil—breast cancer	0.000101	0.00108	CcSEcCtD
Naloxone—Hot flush—Epirubicin—breast cancer	0.0001	0.00108	CcSEcCtD
Naloxone—Vomiting—Chlorambucil—breast cancer	0.0001	0.00108	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	9.98e-05	0.00107	CcSEcCtD
Naloxone—Mental disorder—Paclitaxel—breast cancer	9.94e-05	0.00107	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—breast cancer	9.94e-05	0.00107	CcSEcCtD
Naloxone—Gastrointestinal disorder—Thiotepa—breast cancer	9.88e-05	0.00106	CcSEcCtD
Naloxone—Diarrhoea—Vinblastine—breast cancer	9.87e-05	0.00106	CcSEcCtD
Naloxone—Asthenia—Melphalan—breast cancer	9.85e-05	0.00106	CcSEcCtD
Naloxone—Pain—Thiotepa—breast cancer	9.79e-05	0.00105	CcSEcCtD
Naloxone—Nervous system disorder—Irinotecan—breast cancer	9.7e-05	0.00104	CcSEcCtD
Naloxone—Tension—Paclitaxel—breast cancer	9.7e-05	0.00104	CcSEcCtD
Naloxone—Tachycardia—Mitoxantrone—breast cancer	9.65e-05	0.00104	CcSEcCtD
Naloxone—Asthenia—Goserelin—breast cancer	9.6e-05	0.00103	CcSEcCtD
Naloxone—Skin disorder—Mitoxantrone—breast cancer	9.6e-05	0.00103	CcSEcCtD
Naloxone—Nervousness—Paclitaxel—breast cancer	9.6e-05	0.00103	CcSEcCtD
Naloxone—Diarrhoea—Tamoxifen—breast cancer	9.59e-05	0.00103	CcSEcCtD
Naloxone—Irritability—Methotrexate—breast cancer	9.57e-05	0.00103	CcSEcCtD
Naloxone—Hyperhidrosis—Irinotecan—breast cancer	9.56e-05	0.00103	CcSEcCtD
Naloxone—Hyperhidrosis—Mitoxantrone—breast cancer	9.56e-05	0.00103	CcSEcCtD
Naloxone—Body temperature increased—Vinorelbine—breast cancer	9.48e-05	0.00102	CcSEcCtD
Naloxone—Abdominal pain—Vinorelbine—breast cancer	9.48e-05	0.00102	CcSEcCtD
Naloxone—Nervous system disorder—Gemcitabine—breast cancer	9.44e-05	0.00102	CcSEcCtD
Naloxone—Diarrhoea—Melphalan—breast cancer	9.39e-05	0.00101	CcSEcCtD
Naloxone—Skin disorder—Gemcitabine—breast cancer	9.35e-05	0.00101	CcSEcCtD
Naloxone—Nausea—Chlorambucil—breast cancer	9.35e-05	0.001	CcSEcCtD
Naloxone—Buprenorphine—CYP3A4—breast cancer	9.32e-05	0.0445	CrCbGaD
Naloxone—Hyperhidrosis—Gemcitabine—breast cancer	9.31e-05	0.001	CcSEcCtD
Naloxone—Nervous system disorder—Fluorouracil—breast cancer	9.29e-05	0.000998	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—breast cancer	9.28e-05	0.000997	CcSEcCtD
Naloxone—Tremor—Paclitaxel—breast cancer	9.26e-05	0.000995	CcSEcCtD
Naloxone—Tachycardia—Fluorouracil—breast cancer	9.24e-05	0.000993	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—breast cancer	9.2e-05	0.000989	CcSEcCtD
Naloxone—Hydromorphone—CYP3A4—breast cancer	9.18e-05	0.0439	CrCbGaD
Naloxone—Vomiting—Vinblastine—breast cancer	9.17e-05	0.000986	CcSEcCtD
Naloxone—Diarrhoea—Goserelin—breast cancer	9.16e-05	0.000984	CcSEcCtD
Naloxone—Morphine—CYP2D6—breast cancer	9.1e-05	0.0435	CrCbGaD
Naloxone—Agitation—Paclitaxel—breast cancer	9.08e-05	0.000976	CcSEcCtD
Naloxone—Body temperature increased—Thiotepa—breast cancer	9.05e-05	0.000973	CcSEcCtD
Naloxone—Abdominal pain—Thiotepa—breast cancer	9.05e-05	0.000973	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—breast cancer	8.93e-05	0.00096	CcSEcCtD
Naloxone—Flushing—Docetaxel—breast cancer	8.93e-05	0.00096	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—breast cancer	8.92e-05	0.000959	CcSEcCtD
Naloxone—Vomiting—Tamoxifen—breast cancer	8.91e-05	0.000958	CcSEcCtD
Naloxone—Paraesthesia—Irinotecan—breast cancer	8.88e-05	0.000954	CcSEcCtD
Naloxone—Paraesthesia—Mitoxantrone—breast cancer	8.88e-05	0.000954	CcSEcCtD
Naloxone—Dyspnoea—Mitoxantrone—breast cancer	8.81e-05	0.000947	CcSEcCtD
Naloxone—Dyspnoea—Irinotecan—breast cancer	8.81e-05	0.000947	CcSEcCtD
Naloxone—Angiopathy—Docetaxel—breast cancer	8.73e-05	0.000938	CcSEcCtD
Naloxone—Vomiting—Melphalan—breast cancer	8.72e-05	0.000938	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—breast cancer	8.67e-05	0.000932	CcSEcCtD
Naloxone—Paraesthesia—Gemcitabine—breast cancer	8.65e-05	0.000929	CcSEcCtD
Naloxone—Cardiac disorder—Capecitabine—breast cancer	8.64e-05	0.000929	CcSEcCtD
Naloxone—Flushing—Capecitabine—breast cancer	8.64e-05	0.000929	CcSEcCtD
Naloxone—Chills—Docetaxel—breast cancer	8.63e-05	0.000928	CcSEcCtD
Naloxone—Asthenia—Vinorelbine—breast cancer	8.6e-05	0.000924	CcSEcCtD
Naloxone—Dyspnoea—Gemcitabine—breast cancer	8.59e-05	0.000923	CcSEcCtD
Naloxone—Nausea—Vinblastine—breast cancer	8.57e-05	0.000921	CcSEcCtD
Naloxone—Convulsion—Paclitaxel—breast cancer	8.56e-05	0.00092	CcSEcCtD
Naloxone—Gastrointestinal disorder—Irinotecan—breast cancer	8.54e-05	0.000917	CcSEcCtD
Naloxone—Hypertension—Paclitaxel—breast cancer	8.53e-05	0.000917	CcSEcCtD
Naloxone—Vomiting—Goserelin—breast cancer	8.51e-05	0.000915	CcSEcCtD
Naloxone—Paraesthesia—Fluorouracil—breast cancer	8.5e-05	0.000914	CcSEcCtD
Naloxone—Pain—Mitoxantrone—breast cancer	8.45e-05	0.000909	CcSEcCtD
Naloxone—Pain—Irinotecan—breast cancer	8.45e-05	0.000909	CcSEcCtD
Naloxone—Angiopathy—Capecitabine—breast cancer	8.45e-05	0.000908	CcSEcCtD
Naloxone—Dyspnoea—Fluorouracil—breast cancer	8.44e-05	0.000907	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—breast cancer	8.43e-05	0.000906	CcSEcCtD
Naloxone—Mediastinal disorder—Capecitabine—breast cancer	8.39e-05	0.000902	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—breast cancer	8.39e-05	0.000901	CcSEcCtD
Naloxone—Chills—Capecitabine—breast cancer	8.36e-05	0.000898	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	8.35e-05	0.000898	CcSEcCtD
Naloxone—Nausea—Tamoxifen—breast cancer	8.32e-05	0.000895	CcSEcCtD
Naloxone—Gastrointestinal disorder—Gemcitabine—breast cancer	8.31e-05	0.000894	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—breast cancer	8.25e-05	0.000887	CcSEcCtD
Naloxone—Pain—Gemcitabine—breast cancer	8.24e-05	0.000885	CcSEcCtD
Naloxone—Asthenia—Thiotepa—breast cancer	8.21e-05	0.000883	CcSEcCtD
Naloxone—Diarrhoea—Vinorelbine—breast cancer	8.2e-05	0.000882	CcSEcCtD
Naloxone—Gastrointestinal disorder—Fluorouracil—breast cancer	8.18e-05	0.000879	CcSEcCtD
Naloxone—Mental disorder—Capecitabine—breast cancer	8.16e-05	0.000877	CcSEcCtD
Naloxone—Nausea—Melphalan—breast cancer	8.15e-05	0.000876	CcSEcCtD
Naloxone—Pain—Fluorouracil—breast cancer	8.1e-05	0.00087	CcSEcCtD
Naloxone—Nausea—Goserelin—breast cancer	7.95e-05	0.000855	CcSEcCtD
Naloxone—Nervous system disorder—Paclitaxel—breast cancer	7.91e-05	0.00085	CcSEcCtD
Naloxone—Tachycardia—Paclitaxel—breast cancer	7.87e-05	0.000846	CcSEcCtD
Naloxone—Diarrhoea—Thiotepa—breast cancer	7.83e-05	0.000842	CcSEcCtD
Naloxone—Skin disorder—Paclitaxel—breast cancer	7.83e-05	0.000842	CcSEcCtD
Naloxone—Abdominal pain—Mitoxantrone—breast cancer	7.82e-05	0.00084	CcSEcCtD
Naloxone—Body temperature increased—Mitoxantrone—breast cancer	7.82e-05	0.00084	CcSEcCtD
Naloxone—Abdominal pain—Irinotecan—breast cancer	7.82e-05	0.00084	CcSEcCtD
Naloxone—Body temperature increased—Irinotecan—breast cancer	7.82e-05	0.00084	CcSEcCtD
Naloxone—Morphine—CYP3A4—breast cancer	7.81e-05	0.0373	CrCbGaD
Naloxone—Hyperhidrosis—Paclitaxel—breast cancer	7.8e-05	0.000838	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—breast cancer	7.76e-05	0.000834	CcSEcCtD
Naloxone—Buprenorphine—ABCB1—breast cancer	7.76e-05	0.0371	CrCbGaD
Naloxone—Depression—Methotrexate—breast cancer	7.7e-05	0.000828	CcSEcCtD
Naloxone—Vomiting—Vinorelbine—breast cancer	7.62e-05	0.000819	CcSEcCtD
Naloxone—Body temperature increased—Gemcitabine—breast cancer	7.61e-05	0.000818	CcSEcCtD
Naloxone—Tremor—Capecitabine—breast cancer	7.6e-05	0.000816	CcSEcCtD
Naloxone—Body temperature increased—Fluorouracil—breast cancer	7.49e-05	0.000805	CcSEcCtD
Naloxone—Sweating—Methotrexate—breast cancer	7.4e-05	0.000796	CcSEcCtD
Naloxone—ABCB1—lymph node—breast cancer	7.29e-05	0.00212	CbGeAlD
Naloxone—Vomiting—Thiotepa—breast cancer	7.28e-05	0.000782	CcSEcCtD
Naloxone—Convulsion—Docetaxel—breast cancer	7.26e-05	0.00078	CcSEcCtD
Naloxone—Paraesthesia—Paclitaxel—breast cancer	7.24e-05	0.000778	CcSEcCtD
Naloxone—Hypertension—Docetaxel—breast cancer	7.23e-05	0.000777	CcSEcCtD
Naloxone—Dyspnoea—Paclitaxel—breast cancer	7.19e-05	0.000773	CcSEcCtD
Naloxone—Nausea—Vinorelbine—breast cancer	7.12e-05	0.000765	CcSEcCtD
Naloxone—Asthenia—Irinotecan—breast cancer	7.09e-05	0.000762	CcSEcCtD
Naloxone—Asthenia—Mitoxantrone—breast cancer	7.09e-05	0.000762	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	7.08e-05	0.000761	CcSEcCtD
Naloxone—Hypertension—Capecitabine—breast cancer	7e-05	0.000752	CcSEcCtD
Naloxone—Gastrointestinal disorder—Paclitaxel—breast cancer	6.96e-05	0.000748	CcSEcCtD
Naloxone—Sweating—Epirubicin—breast cancer	6.93e-05	0.000745	CcSEcCtD
Naloxone—Asthenia—Gemcitabine—breast cancer	6.91e-05	0.000743	CcSEcCtD
Naloxone—Pain—Paclitaxel—breast cancer	6.9e-05	0.000741	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	6.86e-05	0.000737	CcSEcCtD
Naloxone—Nausea—Thiotepa—breast cancer	6.8e-05	0.000731	CcSEcCtD
Naloxone—Diarrhoea—Mitoxantrone—breast cancer	6.76e-05	0.000727	CcSEcCtD
Naloxone—Diarrhoea—Irinotecan—breast cancer	6.76e-05	0.000727	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—breast cancer	6.7e-05	0.00072	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—breast cancer	6.67e-05	0.000717	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—breast cancer	6.64e-05	0.000714	CcSEcCtD
Naloxone—Diarrhoea—Gemcitabine—breast cancer	6.59e-05	0.000708	CcSEcCtD
Naloxone—Morphine—ABCB1—breast cancer	6.5e-05	0.031	CrCbGaD
Naloxone—Nervous system disorder—Capecitabine—breast cancer	6.49e-05	0.000697	CcSEcCtD
Naloxone—Diarrhoea—Fluorouracil—breast cancer	6.48e-05	0.000696	CcSEcCtD
Naloxone—Tachycardia—Capecitabine—breast cancer	6.46e-05	0.000694	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—breast cancer	6.43e-05	0.000692	CcSEcCtD
Naloxone—Skin disorder—Capecitabine—breast cancer	6.43e-05	0.000691	CcSEcCtD
Naloxone—Sweating—Doxorubicin—breast cancer	6.41e-05	0.000689	CcSEcCtD
Naloxone—Hyperhidrosis—Capecitabine—breast cancer	6.4e-05	0.000688	CcSEcCtD
Naloxone—Abdominal pain—Paclitaxel—breast cancer	6.37e-05	0.000685	CcSEcCtD
Naloxone—Body temperature increased—Paclitaxel—breast cancer	6.37e-05	0.000685	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—breast cancer	6.29e-05	0.000676	CcSEcCtD
Naloxone—Vomiting—Irinotecan—breast cancer	6.29e-05	0.000676	CcSEcCtD
Naloxone—Vomiting—Mitoxantrone—breast cancer	6.29e-05	0.000676	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—breast cancer	6.25e-05	0.000672	CcSEcCtD
Naloxone—Chills—Methotrexate—breast cancer	6.22e-05	0.000669	CcSEcCtD
Naloxone—Paraesthesia—Docetaxel—breast cancer	6.14e-05	0.00066	CcSEcCtD
Naloxone—Vomiting—Gemcitabine—breast cancer	6.12e-05	0.000658	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—breast cancer	6.09e-05	0.000655	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—breast cancer	6.07e-05	0.000653	CcSEcCtD
Naloxone—Flushing—Epirubicin—breast cancer	6.02e-05	0.000647	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—breast cancer	6.02e-05	0.000647	CcSEcCtD
Naloxone—Vomiting—Fluorouracil—breast cancer	6.02e-05	0.000647	CcSEcCtD
Naloxone—Paraesthesia—Capecitabine—breast cancer	5.94e-05	0.000639	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—breast cancer	5.9e-05	0.000634	CcSEcCtD
Naloxone—Dyspnoea—Capecitabine—breast cancer	5.9e-05	0.000634	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—breast cancer	5.89e-05	0.000633	CcSEcCtD
Naloxone—Nausea—Mitoxantrone—breast cancer	5.87e-05	0.000631	CcSEcCtD
Naloxone—Nausea—Irinotecan—breast cancer	5.87e-05	0.000631	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—breast cancer	5.85e-05	0.000629	CcSEcCtD
Naloxone—Pain—Docetaxel—breast cancer	5.84e-05	0.000628	CcSEcCtD
Naloxone—Chills—Epirubicin—breast cancer	5.82e-05	0.000626	CcSEcCtD
Naloxone—Asthenia—Paclitaxel—breast cancer	5.79e-05	0.000622	CcSEcCtD
Naloxone—Nausea—Gemcitabine—breast cancer	5.72e-05	0.000615	CcSEcCtD
Naloxone—Gastrointestinal disorder—Capecitabine—breast cancer	5.71e-05	0.000614	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—breast cancer	5.68e-05	0.000611	CcSEcCtD
Naloxone—Pain—Capecitabine—breast cancer	5.66e-05	0.000608	CcSEcCtD
Naloxone—Nausea—Fluorouracil—breast cancer	5.62e-05	0.000605	CcSEcCtD
Naloxone—Flushing—Doxorubicin—breast cancer	5.57e-05	0.000599	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—breast cancer	5.57e-05	0.000599	CcSEcCtD
Naloxone—Tension—Epirubicin—breast cancer	5.54e-05	0.000596	CcSEcCtD
Naloxone—Diarrhoea—Paclitaxel—breast cancer	5.52e-05	0.000593	CcSEcCtD
Naloxone—Nervousness—Epirubicin—breast cancer	5.49e-05	0.00059	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—breast cancer	5.45e-05	0.000585	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—breast cancer	5.41e-05	0.000582	CcSEcCtD
Naloxone—Abdominal pain—Docetaxel—breast cancer	5.4e-05	0.000581	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—breast cancer	5.4e-05	0.000581	CcSEcCtD
Naloxone—Chills—Doxorubicin—breast cancer	5.39e-05	0.000579	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—breast cancer	5.26e-05	0.000565	CcSEcCtD
Naloxone—Abdominal pain—Capecitabine—breast cancer	5.23e-05	0.000562	CcSEcCtD
Naloxone—Body temperature increased—Capecitabine—breast cancer	5.23e-05	0.000562	CcSEcCtD
Naloxone—Convulsion—Methotrexate—breast cancer	5.23e-05	0.000562	CcSEcCtD
Naloxone—Agitation—Epirubicin—breast cancer	5.19e-05	0.000558	CcSEcCtD
Naloxone—Tension—Doxorubicin—breast cancer	5.13e-05	0.000551	CcSEcCtD
Naloxone—Vomiting—Paclitaxel—breast cancer	5.13e-05	0.000551	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	5.1e-05	0.000548	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—breast cancer	5.08e-05	0.000546	CcSEcCtD
Naloxone—Asthenia—Docetaxel—breast cancer	4.9e-05	0.000527	CcSEcCtD
Naloxone—Convulsion—Epirubicin—breast cancer	4.89e-05	0.000526	CcSEcCtD
Naloxone—Hypertension—Epirubicin—breast cancer	4.88e-05	0.000524	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—breast cancer	4.83e-05	0.000519	CcSEcCtD
Naloxone—Agitation—Doxorubicin—breast cancer	4.8e-05	0.000516	CcSEcCtD
Naloxone—Nausea—Paclitaxel—breast cancer	4.79e-05	0.000515	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—breast cancer	4.78e-05	0.000514	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.78e-05	0.000513	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—breast cancer	4.76e-05	0.000512	CcSEcCtD
Naloxone—Asthenia—Capecitabine—breast cancer	4.75e-05	0.00051	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—breast cancer	4.68e-05	0.000503	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—breast cancer	4.53e-05	0.000487	CcSEcCtD
Naloxone—Diarrhoea—Capecitabine—breast cancer	4.53e-05	0.000487	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—breast cancer	4.52e-05	0.000486	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—breast cancer	4.51e-05	0.000485	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—breast cancer	4.5e-05	0.000484	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—breast cancer	4.48e-05	0.000481	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—breast cancer	4.46e-05	0.000479	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—breast cancer	4.42e-05	0.000475	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.42e-05	0.000475	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—breast cancer	4.39e-05	0.000472	CcSEcCtD
Naloxone—Vomiting—Docetaxel—breast cancer	4.35e-05	0.000467	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—breast cancer	4.25e-05	0.000457	CcSEcCtD
Naloxone—Pain—Methotrexate—breast cancer	4.21e-05	0.000453	CcSEcCtD
Naloxone—Vomiting—Capecitabine—breast cancer	4.21e-05	0.000452	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—breast cancer	4.18e-05	0.00045	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—breast cancer	4.16e-05	0.000447	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—breast cancer	4.14e-05	0.000445	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—breast cancer	4.14e-05	0.000445	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—breast cancer	4.12e-05	0.000443	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—breast cancer	4.11e-05	0.000442	CcSEcCtD
Naloxone—Nausea—Docetaxel—breast cancer	4.06e-05	0.000436	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—breast cancer	3.98e-05	0.000428	CcSEcCtD
Naloxone—Pain—Epirubicin—breast cancer	3.94e-05	0.000424	CcSEcCtD
Naloxone—Nausea—Capecitabine—breast cancer	3.93e-05	0.000422	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—breast cancer	3.89e-05	0.000419	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—breast cancer	3.89e-05	0.000419	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—breast cancer	3.83e-05	0.000412	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—breast cancer	3.8e-05	0.000409	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—breast cancer	3.68e-05	0.000396	CcSEcCtD
Naloxone—Pain—Doxorubicin—breast cancer	3.65e-05	0.000392	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—breast cancer	3.64e-05	0.000392	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—breast cancer	3.64e-05	0.000392	CcSEcCtD
Naloxone—Asthenia—Methotrexate—breast cancer	3.53e-05	0.00038	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—breast cancer	3.37e-05	0.000362	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—breast cancer	3.37e-05	0.000362	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—breast cancer	3.37e-05	0.000362	CcSEcCtD
Naloxone—Asthenia—Epirubicin—breast cancer	3.31e-05	0.000355	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—breast cancer	3.15e-05	0.000339	CcSEcCtD
Naloxone—Vomiting—Methotrexate—breast cancer	3.13e-05	0.000337	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—breast cancer	3.06e-05	0.000329	CcSEcCtD
Naloxone—Vomiting—Epirubicin—breast cancer	2.93e-05	0.000315	CcSEcCtD
Naloxone—Nausea—Methotrexate—breast cancer	2.93e-05	0.000314	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—breast cancer	2.92e-05	0.000314	CcSEcCtD
Naloxone—Nausea—Epirubicin—breast cancer	2.74e-05	0.000294	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—breast cancer	2.71e-05	0.000291	CcSEcCtD
Naloxone—Nausea—Doxorubicin—breast cancer	2.53e-05	0.000272	CcSEcCtD
Naloxone—SLCO1A2—Metabolism—PTEN—breast cancer	1.43e-06	1.13e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NCOR1—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLA2G4A—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—breast cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NCOR1—breast cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—breast cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLA2G4A—breast cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—breast cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—breast cancer	1.41e-06	1.1e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—breast cancer	1.39e-06	1.09e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—breast cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—breast cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—breast cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—breast cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SRC—breast cancer	1.37e-06	1.08e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—breast cancer	1.37e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—breast cancer	1.37e-06	1.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SRC—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DPYD—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MED12—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—COMT—breast cancer	1.36e-06	1.07e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—breast cancer	1.36e-06	1.07e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—breast cancer	1.36e-06	1.07e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1A1—breast cancer	1.36e-06	1.07e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1A1—breast cancer	1.35e-06	1.06e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—breast cancer	1.35e-06	1.06e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDOA—breast cancer	1.34e-06	1.06e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT2—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ITPR1—breast cancer	1.34e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—breast cancer	1.33e-06	1.05e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—breast cancer	1.33e-06	1.04e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—breast cancer	1.33e-06	1.04e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—breast cancer	1.32e-06	1.04e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—breast cancer	1.32e-06	1.04e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—breast cancer	1.32e-06	1.04e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—breast cancer	1.32e-06	1.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	1.31e-06	1.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA3—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RAF1—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A2—breast cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—breast cancer	1.29e-06	1.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RELA—breast cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CD—breast cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—breast cancer	1.28e-06	1.01e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MAPK3—breast cancer	1.27e-06	1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—breast cancer	1.27e-06	1e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CPT1A—breast cancer	1.27e-06	9.97e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCG2—breast cancer	1.27e-06	9.97e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTR—breast cancer	1.27e-06	9.97e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—breast cancer	1.27e-06	9.94e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK8—breast cancer	1.27e-06	9.94e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CB—breast cancer	1.27e-06	9.94e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MTOR—breast cancer	1.27e-06	9.94e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK3—breast cancer	1.27e-06	9.93e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMS—breast cancer	1.26e-06	9.91e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—breast cancer	1.26e-06	9.91e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK3—breast cancer	1.26e-06	9.9e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—breast cancer	1.26e-06	9.88e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLA2G4A—breast cancer	1.25e-06	9.8e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NCOR1—breast cancer	1.25e-06	9.8e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—breast cancer	1.25e-06	9.8e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HPGDS—breast cancer	1.24e-06	9.77e-06	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—breast cancer	1.24e-06	9.73e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HBA1—breast cancer	1.24e-06	9.71e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—breast cancer	1.23e-06	9.66e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFB1—breast cancer	1.23e-06	9.64e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—breast cancer	1.23e-06	9.63e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—breast cancer	1.22e-06	9.61e-06	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—breast cancer	1.22e-06	9.57e-06	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—breast cancer	1.22e-06	9.57e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—breast cancer	1.22e-06	9.55e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—breast cancer	1.22e-06	9.55e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—breast cancer	1.21e-06	9.49e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ACHE—breast cancer	1.21e-06	9.48e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—breast cancer	1.21e-06	9.48e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—breast cancer	1.2e-06	9.45e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SRC—breast cancer	1.2e-06	9.42e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—breast cancer	1.2e-06	9.42e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—breast cancer	1.2e-06	9.38e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—breast cancer	1.19e-06	9.33e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A1—breast cancer	1.18e-06	9.29e-06	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—breast cancer	1.18e-06	9.26e-06	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—breast cancer	1.18e-06	9.23e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—breast cancer	1.17e-06	9.21e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—breast cancer	1.17e-06	9.18e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAV1—breast cancer	1.17e-06	9.17e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—breast cancer	1.16e-06	9.14e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—breast cancer	1.16e-06	9.13e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAV1—breast cancer	1.16e-06	9.12e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—breast cancer	1.16e-06	9.09e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—breast cancer	1.16e-06	9.08e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—breast cancer	1.15e-06	9.06e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RAF1—breast cancer	1.15e-06	9.03e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RELA—breast cancer	1.14e-06	8.99e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP17A1—breast cancer	1.14e-06	8.97e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—breast cancer	1.14e-06	8.93e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—breast cancer	1.14e-06	8.93e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—breast cancer	1.13e-06	8.9e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—breast cancer	1.13e-06	8.9e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO1—breast cancer	1.13e-06	8.88e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS1—breast cancer	1.13e-06	8.88e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—breast cancer	1.13e-06	8.88e-06	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—breast cancer	1.13e-06	8.85e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MTOR—breast cancer	1.12e-06	8.81e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CB—breast cancer	1.12e-06	8.81e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—breast cancer	1.12e-06	8.81e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.12e-06	8.76e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.11e-06	8.71e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2D6—breast cancer	1.11e-06	8.71e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK3—breast cancer	1.11e-06	8.68e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—breast cancer	1.1e-06	8.66e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—breast cancer	1.1e-06	8.64e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—breast cancer	1.1e-06	8.61e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—breast cancer	1.09e-06	8.59e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA2—breast cancer	1.09e-06	8.55e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—breast cancer	1.08e-06	8.47e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—breast cancer	1.08e-06	8.44e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—breast cancer	1.07e-06	8.42e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK8—breast cancer	1.07e-06	8.4e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—breast cancer	1.07e-06	8.38e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—breast cancer	1.06e-06	8.35e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—breast cancer	1.06e-06	8.3e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FASN—breast cancer	1.06e-06	8.29e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—breast cancer	1.05e-06	8.27e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—breast cancer	1.05e-06	8.26e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—BCHE—breast cancer	1.05e-06	8.26e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—breast cancer	1.04e-06	8.2e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—breast cancer	1.04e-06	8.17e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—breast cancer	1.04e-06	8.16e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—breast cancer	1.03e-06	8.1e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—breast cancer	1.03e-06	8.09e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAV1—breast cancer	1.02e-06	7.99e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SRC—breast cancer	1.01e-06	7.96e-06	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—breast cancer	1.01e-06	7.94e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—breast cancer	1.01e-06	7.93e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—breast cancer	1.01e-06	7.91e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—breast cancer	1e-06	7.89e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NQO1—breast cancer	1e-06	7.88e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A1—breast cancer	1e-06	7.88e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—breast cancer	1e-06	7.87e-06	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—breast cancer	9.96e-07	7.82e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—breast cancer	9.95e-07	7.81e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—breast cancer	9.94e-07	7.8e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—breast cancer	9.88e-07	7.76e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—breast cancer	9.78e-07	7.68e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—breast cancer	9.76e-07	7.66e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—breast cancer	9.72e-07	7.63e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—breast cancer	9.7e-07	7.61e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—breast cancer	9.66e-07	7.59e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—breast cancer	9.63e-07	7.56e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1B1—breast cancer	9.62e-07	7.55e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK8—breast cancer	9.49e-07	7.45e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HSP90AA1—breast cancer	9.43e-07	7.41e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CD—breast cancer	9.35e-07	7.34e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK3—breast cancer	9.35e-07	7.34e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CD—breast cancer	9.3e-07	7.3e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—breast cancer	9.27e-07	7.28e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—breast cancer	9.25e-07	7.26e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—breast cancer	9.23e-07	7.25e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—breast cancer	9.22e-07	7.24e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOA1—breast cancer	9.18e-07	7.2e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—breast cancer	9.13e-07	7.17e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—breast cancer	9.09e-07	7.14e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—breast cancer	9.07e-07	7.12e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP19A1—breast cancer	9.04e-07	7.1e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—STK11—breast cancer	9.04e-07	7.1e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SRC—breast cancer	8.99e-07	7.06e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—breast cancer	8.89e-07	6.98e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—breast cancer	8.83e-07	6.93e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—breast cancer	8.83e-07	6.93e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—breast cancer	8.78e-07	6.89e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—breast cancer	8.76e-07	6.88e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—breast cancer	8.67e-07	6.81e-06	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—breast cancer	8.6e-07	6.75e-06	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—breast cancer	8.53e-07	6.7e-06	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—breast cancer	8.51e-07	6.68e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—breast cancer	8.45e-07	6.63e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—COMT—breast cancer	8.41e-07	6.6e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—breast cancer	8.4e-07	6.59e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—breast cancer	8.37e-07	6.57e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK3—breast cancer	8.29e-07	6.51e-06	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—breast cancer	8.26e-07	6.49e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—breast cancer	8.25e-07	6.48e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ITPR1—breast cancer	8.23e-07	6.46e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CB—breast cancer	8.15e-07	6.4e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CD—breast cancer	8.15e-07	6.4e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CB—breast cancer	8.11e-07	6.36e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—breast cancer	8.09e-07	6.35e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—breast cancer	8.08e-07	6.34e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—breast cancer	8.06e-07	6.33e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—breast cancer	8.04e-07	6.31e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—breast cancer	8.04e-07	6.31e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—breast cancer	8.03e-07	6.31e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—breast cancer	7.92e-07	6.22e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—breast cancer	7.88e-07	6.19e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMS—breast cancer	7.78e-07	6.11e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—breast cancer	7.72e-07	6.06e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—breast cancer	7.69e-07	6.04e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLA2G4A—breast cancer	7.69e-07	6.04e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—breast cancer	7.69e-07	6.04e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOR1—breast cancer	7.69e-07	6.04e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—breast cancer	7.47e-07	5.86e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—breast cancer	7.46e-07	5.86e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—breast cancer	7.45e-07	5.85e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—breast cancer	7.36e-07	5.78e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A1—breast cancer	7.29e-07	5.72e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—breast cancer	7.23e-07	5.68e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—breast cancer	7.14e-07	5.6e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CB—breast cancer	7.1e-07	5.58e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—breast cancer	7.04e-07	5.53e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—breast cancer	7.04e-07	5.52e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—breast cancer	7e-07	5.5e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—breast cancer	6.84e-07	5.37e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—breast cancer	6.83e-07	5.36e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—breast cancer	6.8e-07	5.34e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—breast cancer	6.62e-07	5.2e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—breast cancer	6.33e-07	4.97e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—breast cancer	6.3e-07	4.95e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAV1—breast cancer	6.27e-07	4.92e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—breast cancer	6.14e-07	4.82e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—breast cancer	6.06e-07	4.76e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—breast cancer	5.71e-07	4.48e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—breast cancer	5.59e-07	4.39e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CD—breast cancer	5.02e-07	3.94e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—breast cancer	4.97e-07	3.9e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—breast cancer	4.96e-07	3.89e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—breast cancer	4.94e-07	3.88e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—breast cancer	4.74e-07	3.72e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CB—breast cancer	4.38e-07	3.44e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—breast cancer	4.34e-07	3.4e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—breast cancer	4.33e-07	3.4e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—breast cancer	4.06e-07	3.19e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—breast cancer	4.04e-07	3.17e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—breast cancer	3.78e-07	2.97e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—breast cancer	3.54e-07	2.78e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—breast cancer	2.67e-07	2.09e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—breast cancer	2.18e-07	1.71e-06	CbGpPWpGaD
